EGFR and colorectal carcinoma: For CRC, EGFR (anti-EGFR monoclonal antibody: cetuximab) and VEGF (anti-VEGF monoclonal antibody: bevacizumab) targeting is the standard therapy that prolongs survival in patients with metastatic disease19, and previous studies have shown that molecular imaging of EGFR27 and VEGF28, 29 can be performed in vivo, so we decided that the FRES imaging targets should be EGFR and VEGF.